摘要
目的:观察拉贝洛尔联合硝苯地平治疗子痫前期患者的效果。方法:选取2021年6月至2023年6月该院收治的80例子痫前期患者进行前瞻性研究,按照随机数字表法将其分为对照组和观察组各40例。两组均予以常规治疗,在此基础上,对照组予以硝苯地平治疗,观察组在对照组基础上联合拉贝洛尔治疗,两组均连续治疗1个月。比较两组临床疗效,治疗前后血压(收缩压、舒张压)、24 h尿蛋白定量、凝血功能指标[凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、凝血酶时间(TT)、纤维蛋白原(FIB)]、胎儿脐动脉血流指标[收缩压与舒张压的比值(S/D)、搏动指数(PI)、阻力指数(RI)]水平,不良妊娠结局发生率,以及不良反应发生率。结果:观察组治疗总有效率为97.50%(39/40),高于对照组的80.00%(32/40),差异有统计学意义(P<0.05);治疗后,观察组收缩压、舒张压、24 h尿蛋白定量水平均低于对照组,差异有统计学意义(P<0.05);治疗后,观察组PT、APTT、TT长于对照组,FIB水平低于对照组,差异均有统计学意义(P<0.05);治疗后,观察组胎儿脐动脉S/D、PI、RI均低于对照组,差异有统计学意义(P<0.05);随访至分娩结束,观察组不良妊娠结局发生率为17.50%(7/40),低于对照组的55.00%(22/40),差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:拉贝洛尔联合硝苯地平治疗子痫前期患者可提高治疗总有效率,降低血压、24 h尿蛋白定量、胎儿脐动脉血流指标水平和不良妊娠结局发生率,改善凝血功能指标水平,效果优于单纯硝苯地平治疗。
Objective:To observe effects of Labetalol combined with Nifedipine in treatment of patients with preeclampsia.Methods:A prospective study was conducted on 80 patients with preeclampsia admitted to the hospital from June 2021 to June 2023.According to the random number table method,they were divided into control group and observation group,40 cases in each group.Both groups were given routine treatment.On this basis,the control group was treated with Nifedipine,while the observation group was treated with Labetalol on the basis of that of the control group.Both groups were treated continuously for 1 month.The clinical efficacy,the levels of blood pressure(systolic blood pressure,diastolic blood pressure),the 24 h urine protein quantitative,the coagulation function index [prothrombin time(PT),activated partial thromboplastin time(APTT),thrombin time(TT),fibrinogen(FIB)],and the fetal umbilical artery blood flow index [ratio of systolic blood pressure to diastolic blood pressure(S/D),pulsatility index(PI),resistance index(RI)],the incidence of adverse pregnancy outcomes,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 97.50%(39/40),which was higher than 80.00%(32/40) of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of systolic blood pressure,diastolic blood pressure and 24 h urinary protein in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the PT,APTT and TT in the observation group were longer than those in the control group,the level of FIB was lower than that in the control group,and the differences were statistically significant(P<0.05).After the treatment,the fetal umbilical artery S/D,PI and RI in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).From follow-up to delivery,the incidence of adverse pregnancy outcomes in the observation group was 17.50%(7/40),which was lower than 55.00%(22/40) in the control group,the difference was statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Labetalol combined with Nifedipine in the treatment of the patients with preeclampsia can improve the total effective rate of treatment,reduce the blood pressure,24 h urine protein quantification,fetal umbilical artery blood flow index levels and incidence of adverse pregnancy outcomes,and improve the levels of coagulation function indexes.Moreover,it is superior to single Nifedipine treatment.
作者
秦小艳
QIN Xiaoyan(1^(st)Ward of Department of Obstetrics of Maternal and Child Health Hospital of Jiaozuo City,Jiaozuo 454000 Henan,China)
出处
《中国民康医学》
2024年第13期92-94,104,共4页
Medical Journal of Chinese People’s Health
关键词
子痫前期
拉贝洛尔
硝苯地平
血压
妊娠结局
凝血功能
不良反应
Preeclampsia
Labetalol
Nifedipine
Blood pressure
Pregnancy outcome
Coagulation function
Adverse reaction
